Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by June 3, 2025, to serve as lead plaintiff [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3]. Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that affected the shipment of eleven products [4]. - Defendants allegedly downplayed the impact of the warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection and remediation efforts [5]. - The misleading statements led investors to purchase Viatris securities at artificially inflated prices, resulting in damages when the true information became public [5].

NEW YORK, May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=150490&from=4CLASS PERIOD: August 8, 2024 to February ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Viatris Inc. regarding a class action lawsuit related to misleading statements about the company's Indore, India facility inspection and its subsequent financial performance [1][3]. Group 1: Allegations and Financial Impact - The class period for the lawsuit is from August 8, 2024, to February 26, 2025 [3]. - The complaint alleges that Viatris misrepresented the significance of a warning letter from the FDA regarding its Indore facility, downplaying it as a "minor headwind" [3]. - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024, Viatris attributed its below-expectation guidance to the financial impact from the Indore facility warning letter and import alert [3]. - On February 27, 2025, Viatris' stock price fell from $11.24 to $9.53, a decline of approximately 15.21% in one day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].